P
Prosensa
Biotech & Life Sciences · Leiden, Netherlands · Founded 2002
Provides RNA-based therapeutics for the treatment of genetic disorders, infections and cancers MoreLess
Prosensa Holding N.V. operated as a biopharmaceutical company focused on the discovery and development of RNA-modulating therapeutics for rare genetic diseases. The company's primary focus was on addressing Duchenne muscular dystrophy (DMD), a debilitating genetic disorder. It was founded in 2002 as a spin-off from the Leiden University Medical Center in the Netherlands. The founders included Giles Campion, who later served as CEO, and Judith van Deutekom. The company's scientific foundation was built upon the research of Judith van Deutekom and her team at the university, who were pioneers in the development of exon skipping technology.
Prosensa's lead product candidate was drisapersen, an investigational drug designed to treat a specific subset of DMD patients. The company's therapeutic approach, known as exon skipping, aimed to correct the genetic defect that causes DMD by producing a shorter but functional version of the dystrophin protein, which is essential for muscle function. This approach positioned Prosensa at the forefront of genetic medicine for rare diseases. The business model revolved around extensive research and development, clinical trials, and strategic partnerships. A significant partnership was established with GlaxoSmithKline (GSK) for the development and commercialization of its DMD portfolio; however, this collaboration was terminated in 2014 following disappointing clinical trial results for drisapersen.
Despite the clinical setbacks, Prosensa's expertise and intellectual property in RNA therapeutics remained valuable. The company had a pipeline of other drug candidates for DMD and other rare diseases. In a significant milestone for the company and a notable event in the biotech industry, Prosensa was acquired by BioMarin Pharmaceutical Inc. in November 2014. The acquisition, valued at approximately $840 million, provided BioMarin with Prosensa's portfolio of drug candidates for rare genetic diseases, including drisapersen.
Keywords: Duchenne muscular dystrophy, RNA therapeutics, exon skipping, rare diseases, biopharmaceutical, drisapersen, genetic medicine, clinical trials, Leiden University, BioMarin
Company overview
Prosensa company information
The essential company record, classifications and operating signals in one place.
Valuation & funding
Prosensa funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2014 | $680M | $680M | BioMarin Pharmaceutical | — |
| GRANT✓Other financing | Jul 2014 | $200K | — | Parent Project Muscular Dystrophy | — |
| IPO✓Exit | Jun 2013 | $0 | — | Undisclosed | — |
| LATE VC✓Equity / VC | Dec 2012 | $23M | $92M | Eurazeo · Abingworth · MedSciences Capital · EQT Life Sciences | — |
| LATE VC✓Equity / VC | Jan 2012 | $33M | $132M | NEA | — |
| SERIES B✓Equity / VC | Dec 2008 | Gimv · Eurazeo | — | ||
| SERIES A✓Equity / VC | Feb 2007 | Abingworth · EQT Life Sciences | — | ||
| SPINOUT✓Other financing | Jan 2002 | Leiden University | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $9.8M | 0% | −$18M | -186.2% |
| 2025 | $9.8M | 0% | −$18M | -186.2% |
| 2024 | $9.8M | 0% | −$18M | -186.2% |
| 2023 | $9.8M | 0% | ||
| 2022 | $9.8M | 0% | ||
| 2021 | $9.8M | 0% | ||
| 2020 | $9.8M | — |
Growth signals
Prosensa website traffic
Latest recorded traffic for Prosensa is 120 monthly website visits, down 20% over the last three months.
Comparisons
Prosensa compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Prosensa investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Prosensa's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on Prosensa's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Prosensa has talent and traffic
In the news
Latest news about Prosensa
Recent press, funding announcements, and product moves mentioning Prosensa — open to read from the original sources.
Market sentiment
What the market is saying about Prosensa
An AI-synthesized read of the highest-engagement posts about Prosensa on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Prosensa’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.